Please wait while the formulary information is being retrieved.
BETHKIS (TOBRAMYCIN)
- Respiratory cystic fibrosis p. aeruginosa colonization
- Synergy for p. aeruginosa infection in cystic fibrosis
300 mg/4 mL solution for nebulization
- Inhale 4 milliliters (300 mg) via nebulizer by inhalation route every12 hours
Respiratory cystic fibrosis p. aeruginosa colonization
- Inhale 4 milliliters (300 mg) via nebulizer by inhalation route every12 hours
- Inhale 4 milliliters (300 mg) via nebulizer by inhalation route every12 hours for 28 days
Synergy for p. aeruginosa infection in cystic fibrosis
- Inhale 4 milliliters (300 mg) via nebulizer by inhalation route every12 hours
- Inhale 4 milliliters (300 mg) via nebulizer by inhalation route every12 hours for 28 days
- typhoid vaccine
- Vivotif Berna Vaccine
Contraindicated
- abobotulinumtoxinA
- Anectine
- atracurium
- Botox
- Botox Cosmetic
- cisatracurium
- Compound 347
- Dysport
- enflurane
- Forane
- incobotulinumtoxinA
- isoflurane
- Myobloc
- Nimbex
- onabotulinumtoxinA
- pancuronium
- Quelicin
- rimabotulinumtoxinB
- rocuronium
- succinylcholine chloride
- Terrell
- vecuronium bromide
- Xeomin
- Zemuron
Severe
Moderate
- ampicillin sodium
- ampicillin-sulbactam
- Bicillin C-r
- Bicillin L-a
- Cedax
- cefaclor
- cefadroxil
- cefazolin
- cefazolin in dextrose (iso-os)
- cefdinir
- cefepime
- cefepime in dextrose 5 %
- cefepime in dextrose,iso-osm
- cefotaxime
- cefotetan
- cefotetan in dextrose, iso-osm
- cefoxitin
- cefoxitin in dextrose 3.9 %
- cefoxitin in dextrose, iso-osm
- cefpodoxime
- cefprozil
- ceftazidime
- ceftazidime in D5W
- ceftazidime-dextrose (iso-osm)
- ceftibuten
- Ceftin
- ceftriaxone
- ceftriaxone in dextrose,iso-os
- cefuroxime axetil
- cefuroxime in sterile water
- cefuroxime sodium
- cefuroxime-dextrose (iso-osm)
- cephalexin
- Claforan
- ethacrynate sodium
- Fortaz
- Fortaz In Dextrose 5 %
- furosemide
- Keflex
- Lasix
- mannitol 10 %
- mannitol 15 %
- mannitol 20 %
- mannitol 25 %
- mannitol 5 %
- Maxipime
- Mefoxin In Dextrose (iso-osm)
- nafcillin
- nafcillin in dextrose iso-osm
- Osmitrol 10 %
- Osmitrol 15 %
- Osmitrol 20 %
- Osmitrol 5 %
- oxacillin
- oxacillin in dextrose(iso-osm)
- penicillin G benzathine
- penicillin G benzathine & proc
- penicillin G pot in dextrose
- penicillin G potassium
- penicillin G procaine
- penicillin G sodium
- Pfizerpen-g
- piperacillin-tazobactam
- piperacillin-tazobactam-dextrs
- Rocephin
- Sodium Edecrin
- Tazicef
- ticarcillin-clavulanate
- Timentin
- Unasyn
- Zinacef
- Zinacef In Sterile Water
- Zosyn
- Zosyn In Dextrose (iso-osm)
- None
Contraindicated
- Disorder of the 8th cranial nerve
- Kidney disease with reduction in GFR
- Myasthenia gravis
- Parkinsonism
- Tinnitus
- Vertigo
Severe
Moderate
- Asthma
- Chronic obstructive pulmonary disease
BETHKIS (TOBRAMYCIN)
- Respiratory cystic fibrosis p. aeruginosa colonization
- Synergy for p. aeruginosa infection in cystic fibrosis
- None
- Cough
- Diarrhea
- Dyspnea
- Fever
- Headache disorder
- Hemoptysis
- Voice change
More Frequent
Severe
Less Severe
- None
- Dysgeusia
- Laryngitis
- Myalgias
- Nausea
- Non-cardiac chest pain
- Pharyngitis
- Tinnitus
- Vomiting
- Weight loss
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Aphonia
- Auditory neurotoxicity
- Bronchospastic pulmonary disease
- Nephrotoxicity
- Neuromuscular blockade
- Ototoxicity
Less Severe
- Anorexia
- Ataxia
- Dizziness
- Pain in oropharynx
- Pruritus of skin
- Skin rash
- Urticaria
- Vertigo
- Wheezing
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Tobramycin (Inhal)
Safety and efficacy under the age of 6 years not established.
- 1 Day – 6 Years
- Safety and efficacy under the age of 6 years not established.
Tobramycin (inh)
- Severity Level:
2
- Additional Notes: Systemic absorption is likely low after oral inhalation
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Tobramycin
Poor oral absorption; unlikely clinically significant levels in infant
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Excreted | Not known; no or inclusive data | Poor oral absorption; unlikely clinically significant levels in infant |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Tobramycin (inhalation)
Renal- Monitor renal function with known or suspected renal dysfunction. Neuro/Psych- Use with caution with underlying neuromuscular disorder. Test hearing if at risk for ototoxicity or with anticipated prolonged therapy.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | Y | N | N | Y | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- None
| Respiratory cystic fibrosis p. aeruginosa colonization | |
| B96.5 | Pseudomonas (aeruginosa) (mallei) (pseudomallei) as the cause of diseases classified elsewhere |
| E84.0 | Cystic fibrosis with pulmonary manifestations |
| Synergy for p. aeruginosa infection in cystic fibrosis | |
| B96.5 | Pseudomonas (aeruginosa) (mallei) (pseudomallei) as the cause of diseases classified elsewhere |
| E84.0 | Cystic fibrosis with pulmonary manifestations |
| 0-9 | A-Z |
|---|---|
| B96.5 | Pseudomonas (aeruginosa) (mallei) (pseudomallei) as the cause of diseases classified elsewhere |
| B96.5 | Pseudomonas (aeruginosa) (mallei) (pseudomallei) as the cause of diseases classified elsewhere |
| E84.0 | Cystic fibrosis with pulmonary manifestations |
| E84.0 | Cystic fibrosis with pulmonary manifestations |
Formulary Reference Tool